Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

about

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition

P2860

Q38648408-B575CDE4-EFEF-46A9-A0FF-36294F9E7FDE Q57167862-53DEFD46-CB47-47FD-88CD-4143ACAF3447

P2860

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

Item

http://www.wikidata.org/entity/Q38382840

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

@en

type

Item

label

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

@en

prefLabel

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

@en

P1476

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

@en

P2093

Adriana D Corben

http://www.w3.org/2001/XMLSchema#string

Clifford Hudis

http://www.w3.org/2001/XMLSchema#string

Komal Jhaveri

http://www.w3.org/2001/XMLSchema#string

Muzaffar Akram

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Neil Iyengar

http://www.w3.org/2001/XMLSchema#string

Patrick G Morris

http://www.w3.org/2001/XMLSchema#string

Rita A Sakr

http://www.w3.org/2001/XMLSchema#string

Russell Towers

http://www.w3.org/2001/XMLSchema#string

Sarat Chandarlapaty

http://www.w3.org/2001/XMLSchema#string

P2860

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

HSP90 inhibitors for cancer therapy and overcoming drug resistance

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

HSP90 and the chaperoning of cancer

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.

P304

276-283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLBC.2015.11.004

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Larry Norton

P577

2015-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26726007

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5242238

http://www.w3.org/2001/XMLSchema#string

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

about

P2860

P2860

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932